Bio Partnering APAC 2019
Shanghai , Sept 24-25, 2019
Against the background of increasing government policy support, exciting biotechnology breakthroughs and growing venture capital investment, themed on “R&D Strategy Innovation under New Regulatory Policy, Collaboration Opportunity under New Global Situation”, Bio Partnering APAC 2019 provided with the latest knowledge, tools and expertise to set own global business strategy.
Echo Hindle-Yang, Founder & CEO at MSQ Ventures, was invited to participate in the panel discussion "Collaboration Innovation: The New Opportunities under Drug Regulatory Reform both in China and Abroad" on September 24, at 9 AM (CST).
As the supporting organization, MSQ also invited our clients: Sijme Zeilemaker, Senior Director of Business Development of Immunicum AB (IMMU) and Emmet Browne, CEO of Nuritas to also speech at the event.
Given the current global competitive landscape and challenges existing in the healthcare industry, all speakers presented their ideas and thoughts on the latest collaboration opportunities when it comes to drug innovation, new therapy development and regulatory reform.
See more details about this event, click here.